| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2018NatCo...9.4098M |
| P356 | DOI | 10.1038/S41467-018-06621-3 |
| P932 | PMC publication ID | 6173722 |
| P698 | PubMed publication ID | 30291246 |
| P50 | author | Francesca Fallarino | Q39062847 |
| Romain Hardet | Q49740489 | ||
| P2093 | author name string | Alban Vignaud | |
| Federico Mingozzi | |||
| Giuseppe Ronzitti | |||
| Christopher Roy | |||
| Christian Leborgne | |||
| Fanny Collaud | |||
| Laetitia van Wittenberghe | |||
| Marcelo Simon Sola | |||
| Severine Charles | |||
| Amine Meliani | |||
| Solenne Marmier | |||
| Florence Boisgerault | |||
| Giorgia Manni | |||
| Helena Costa Verdera | |||
| Olivier Christophe | |||
| Petr Ilyinskii | |||
| Takashi Kei Kishimoto | |||
| Alicia Michaud | |||
| P2860 | cites work | Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles. | Q51602149 |
| Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors | Q89777435 | ||
| Safety and efficacy of subretinal readministration of a viral vector in large animals to treat congenital blindness | Q28279062 | ||
| Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses | Q28595509 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| AAV2 gene therapy readministration in three adults with congenital blindness. | Q30587265 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Adeno-associated virus vectors can be efficiently produced without helper virus | Q34479933 | ||
| B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study | Q34763584 | ||
| Gene therapy and pediatric liver disease. | Q34769121 | ||
| Long-term safety and efficacy of factor IX gene therapy in hemophilia B. | Q34783922 | ||
| Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer | Q34985105 | ||
| Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance | Q34985424 | ||
| A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. | Q35568505 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Hepatic gene transfer in neonatal mice by adeno-associated virus serotype 8 vector. | Q35988663 | ||
| Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. | Q36007714 | ||
| Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B. | Q36085401 | ||
| AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes | Q36106408 | ||
| Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates | Q36143384 | ||
| How to calculate sample size in animal studies? | Q37303624 | ||
| A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome | Q37313599 | ||
| Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. | Q37562066 | ||
| AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. | Q37690491 | ||
| Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges | Q37866086 | ||
| Monogenic diseases that can be cured by liver transplantation | Q38098339 | ||
| Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors | Q38187651 | ||
| A pilot study on using rapamycin-carrying synthetic vaccine particles (SVP) in conjunction with enzyme replacement therapy to induce immune tolerance in Pompe disease | Q38650286 | ||
| Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. | Q38676926 | ||
| Human regulatory B cells in health and disease: therapeutic potential. | Q39156034 | ||
| Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. | Q39501844 | ||
| Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system | Q39784405 | ||
| A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies | Q39803858 | ||
| Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. | Q40109350 | ||
| Successful Repeated Hepatic Gene Delivery in Mice and Non-human Primates Achieved by Sequential Administration of AAV5ch and AAV1. | Q40166892 | ||
| Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation | Q40188801 | ||
| Long-term effects of systemic gene therapy in a canine model of myotubular myopathy | Q40261444 | ||
| Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques. | Q40487347 | ||
| Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes | Q41907025 | ||
| Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape. | Q41928007 | ||
| Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy | Q41999615 | ||
| Overcoming preexisting humoral immunity to AAV using capsid decoys | Q42056009 | ||
| Life-long correction of hyperbilirubinemia with a neonatal liver-specific AAV-mediated gene transfer in a lethal mouse model of Crigler-Najjar Syndrome | Q42203199 | ||
| Hemophilia Gene Therapy: Caught Between a Cure and an Immune Response | Q42921117 | ||
| Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors | Q43473893 | ||
| Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors | Q44258968 | ||
| Assessment of a passive immunity mouse model to quantitatively analyze the impact of neutralizing antibodies on adeno-associated virus-mediated gene transfer | Q45172007 | ||
| CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
| High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency | Q45855465 | ||
| Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients | Q45864185 | ||
| Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes | Q45865401 | ||
| Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy | Q45873849 | ||
| Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. | Q45875499 | ||
| AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. | Q45875670 | ||
| Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity | Q47222860 | ||
| Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. | Q47287713 | ||
| Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase. | Q47301525 | ||
| Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an AAV vector expressing human SMN. | Q49600921 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| nanoparticle | Q61231 | ||
| P304 | page(s) | 4098 | |
| P577 | publication date | 2018-10-05 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration | |
| P478 | volume | 9 |
| Q89733487 | 10th European immunogenicity platform open symposium on immunogenicity of biopharmaceuticals |
| Q92876148 | AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer |
| Q64040883 | Adeno-associated virus vector as a platform for gene therapy delivery |
| Q91655909 | Advancements in AAV-mediated Gene Therapy for Pompe Disease |
| Q90311831 | Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems |
| Q97519097 | B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin |
| Q89500035 | Blockade of the costimulatory CD28-B7 family signal axis enables repeated application of AAV8 gene vectors |
| Q92825245 | Capsid-specific removal of circulating antibodies to adeno-associated virus vectors |
| Q96306450 | De novo design of functional zwitterionic biomimetic material for immunomodulation |
| Q97423868 | Development of AAV Variants with Human Hepatocyte Tropism and Neutralizing Antibody Escape Capacity |
| Q92547654 | Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity |
| Q92635178 | Emerging Concepts and Challenges in Rheumatoid Arthritis Gene Therapy |
| Q99579530 | Gene Therapy for Hemophilia: Facts and Quandaries in the 21st Century |
| Q91972798 | Gene therapy for progressive familial intrahepatic cholestasis type 3 in a clinically relevant mouse model |
| Q94502776 | Human Immune Responses to Adeno-Associated Virus (AAV) Vectors |
| Q96127660 | IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies |
| Q92863312 | Immune Response Mechanisms against AAV Vectors in Animal Models |
| Q92851595 | Immune Responses to Viral Gene Therapy Vectors |
| Q90000829 | Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates |
| Q90836400 | Immunogenicity of Protein Pharmaceuticals |
| Q90012812 | Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome |
| Q92487813 | Progress and challenges of gene therapy for Pompe disease |
| Q89696214 | Recent highlights and advances in cardiac gene therapy |
| Q96292693 | Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase |
| Q99561220 | Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme |
| Q97644525 | T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020 |
| Q93190169 | Temporary Reduction of Membrane CD4 with the Antioxidant MnTBAP Is Sufficient to Prevent Immune Responses Induced by Gene Transfer |
| Q91973492 | The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases |
| Q94464382 | The Immune Response to the fVIII Gene Therapy in Preclinical Models |
| Q90129514 | The Landscape of Early Clinical Gene Therapies outside of Oncology |
| Q102075314 | The once and future gene therapy |
| Q96109656 | Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates |
| Q90595648 | Update on clinical gene therapy for hemophilia |
Search more.